Alliances
Findings from a Phase III long-term extension study show a once-daily therapy consisting of relugolix with estradiol and norethindrone acetate leads to clinically meaningful reductions in menstrual pain and non-menstrual pelvic pain over one year in women with endometriosis.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 26, 2021.
Ten pharmaceutical companies have joined forces again to launch Accumulus Synergy Inc., a non-profit effort to pool data in the cloud and interact with regulators, in the hopes of speeding the drug approval process.
Servier and MiNA Therapeutics are partnering on small activating RNA (saRNA) therapies to treat neurological diseases. saRNA is an entirely new class of drugs.
NEUVOGEN’s official strategy revolves around covering the entire immune system so that the tumor cannot perform an “immune escape”. Past immune priming efforts have fallen short because they focus on only a handful of important targets that some tumor cells may not express, thereby allowing them to escape the therapy’s boundaries.
Indianapolis-based Eli Lilly is betting big on clinical-stage oncology company Merus, agreeing to pay up to $1.6 billion to the Netherlands-based biotech for a research and development collaboration focused on up to three early experimental cancer drugs.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 19, 2021.
Major players in the biotech industry are moving full steam ahead in their 2021 operations goals despite the ongoing pandemic, with global pharmaceutical giant Takeda being no exception.
The two companies will work together to use dendritic cells to develop immune tolerance.
In an interview with BioSpace, Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, outlined Bayer’s thought process for opening its purse strings and diving into the deep end of the cell and gene therapy space.
PRESS RELEASES